Kestra Medical Technologies, Ltd.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Kestra Medical Technologies, Ltd. (KMTS) develops and commercializes wearable medical devices and digital healthcare solutions focused on protecting patients at risk of sudden cardiac arrest through intuitive, intelligent, and connected diagnostic and therapeutic technologies; its core Cardiac Recovery System platform integrates the ASSURE Wearable Cardioverter Defibrillator (WCD) for continuous monitoring and automatic defibrillation of ventricular arrhythmias, the Kestra CareStation cloud-based remote patient data platform for provider oversight and notifications, the ASSURE patient mobile application for self-management, activity tracking, educational content, and data transmission, and the ASSURE Wearable ECG for post-WCD monitoring using the same SensorFit garment and algorithms. Kestra Medical Technologies operates primarily in the cardiovascular disease segment, targeting heart failure patients and those with low left ventricular ejection fraction awaiting therapy eligibility; it serves healthcare providers including over 550 hospitals across the United States with in-network payer coverage reaching 285 million lives, and maintains a presence in Ireland. Founded in 2014 and headquartered in Kirkland, Washington, the company employs approximately 300 people and has grown its clinical registry beyond 20,000 patients. In July 2024, Kestra Medical Technologies completed an oversubscribed $196 million financing round co-led by Andera Partners, Ally Bridge Group, Longitude Capital, and Omega Funds, with participation from T. Rowe Price Investment Management, Eventide Asset Management, Gilmartin Capital, Bain Capital, and Endeavour Vision, funding commercial expansion of the ASSURE system; in March 2025, it priced an upsized initial public offering on Nasdaq at $17 per share, raising $202 million; fiscal year 2025 delivered record revenue of $59.8 million, up 115% year-over-year, with 3,903 ASSURE prescriptions in Q4 alone (up 43%) and gross margins expanding to 40.5%, alongside commercial team growth to 80 sales territories and FY2026 revenue guidance of $85 million.
Company News
Kestra Medical Technologies to Report First Quarter Fiscal 2027 Financial Results on September 14
Kestra Appoints Curtis Kopf as Senior Vice President of Customer Experience
Here Are Monday’s Top Wall Street Analyst Research Calls: Akamai Technologies, Apple, Dicks Sporting Goods, Domino’s Pizza, Doximity, NetApp, SanDisk, Trade Desk, and More
Strength Seen in Kestra Medical Technologies, Ltd. (KMTS): Can Its 8.1% Jump Turn into More Strength?
Kestra Medical Technologies, Ltd. (KMTS) Q4 2026 Earnings Call Transcript
Kestra Medical Technologies, Ltd. (KMTS) Reports Q4 Loss, Tops Revenue Estimates
Kestra Medical Technologies Q4 Earnings Call Highlights
Kestra Medical Technologies Secures Up to $200 Million of Non-Dilutive Financing
Kestra Medical Technologies Reports Fourth Quarter and Fiscal Year 2026 Financial Results
Kestra Medical Technologies to Report Fourth Quarter Fiscal 2026 Financial Results on July 14
What a $312,000 Kestra Insider Sale Signals After 25% Stock Gains
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares
Kestra Medical Technologies, Ltd. (KMTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Kestra Medical Technologies to Present at the BofA Securities 2026 Healthcare Conference
Kestra Showcases Accelerated Innovation at HRS 2026
Kestra Medical Technologies Named a 2026 USA TODAY Top Workplaces Award Winner
The Kestra Director Who Built and Sold a Device Company Keeps Buying Stock
Kestra Medical Technologies Named Finalist for 2026 GeekWire “Deal of the Year”
Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $304,050.00 in Stock
Kestra Medical Technologies, Ltd. (KMTS) Q3 2026 Earnings Call Transcript